Search
  • Global Cancer Technology

A Novel Treatment Modality for COVID-19

Global Cancer Technology is Developing a Light-emitting Nanoparticle Which May Selectively Target, Bind and Inactivate Coronavirus Virions


San Diego, CA (December 30, 2020): COVID-19 is relentless, showing no signs of abating any time soon. December 2020 is the deadliest month on record since the pandemic began with more than 63,000 Americans deceased before Christmas as a result of the disease. Worldwide, more than 81 million cases and 1.8 million deaths have been reported. Innovative treatments are critically needed to support healthcare workers and hospitals that continue to operate at or beyond capacity. Global Cancer Technology (GCT) has licensed a technology developed at the UCSD Medical System for a novel treatment that is designed to selectively target and inactivate coronavirus virions. “The vaccines developed in record time offer us all great hope,” said John Clark, CEO and founder of GCT. “However, their supply chain delivery challenges and high costs per dose will limit how quickly billions of people worldwide can be inoculated. In the interim, we need a treatment to aid those who are hospitalized with the virus and at risk of dying from it.” In the early phase of the global pandemic, the anti-malaria medication, hydroxychloroquine, was touted as potentially beneficial for the treatment of COVID-19 but the FDA later did not encourage its use for this indication. Today’s standard of care for hospitalized patients requires the intravenous injection of Remdesivir®, a broad spectrum anti-viral medication. As the number of hospitalizations and deaths continue to rise, with health authorities warning of a “nightmarish” winter toll on our healthcare workers and our society, additional treatment modalities that can work independently, or synergistically in combination with Remdesivir, are desperately needed. The GCT team of scientists and clinicians is developing a novel COVID-19 treatment based on the photo-dynamic properties of nanocrystal scintillators. These nanoparticles readily absorb X-rays, even when exposed to low doses, and transform that radiation into bursts of ultra-violet light when activated. GCT has modified the surface of these nanoparticles with COVID-specific binding proteins. These nanoparticles can be delivered directly to the patient’s infected lungs via ventilators and respirators, or via intravenous injection if the lungs are obstructed by fluids. Once inside the lungs, the nanoparticles are designed to behave like magnets that selectively and irreversibly bind their targets – protein receptors on the spikes that are infamously displayed on the exterior of COVID-19 virus particles. They can then be activated with a low dose of radiation delivered to the lungs only: as low as 1/400th the dose of standard chest X-ray is effective. The nanoparticles are designed to absorb X-ray radiation and transform it into a burst of short wavelength ultra-violet-A light. UV-A light is known to damage coronavirus particles and to inactivate them. “What this technology has the potential to do is to engage and destroy virus particles directly in the lungs of COVID patients,” explained Clark. In simple terms, GCT’s nanoparticle scintillator technology platform can be readily and affordably deployed worldwide. “Due to the elegant simplicity of this approach,” Clark continued, “it also has the potential for widespread use globally given its relatively low cost and accessibility from an ease-of-use application perspective. This is going to be particularly important given the cold chain logistics challenges associated with deploying the two vaccines that have been approved and how long it will take to inoculate billions of people around the world.” Additional funding is needed to further develop the particles and subsequently test the nanoparticles in cell-based and in vivo systems as well as to conduct preclinical studies which could lead to a formal line of research to support an IND application to the FDA. About Global Cancer Technology: Global Cancer Technology (GCT) is an emerging biopharmaceutical company that is pre-revenue and financially operates as a medical technology holding company. GCT holds numerous patents and other assets including licenses to commercialize nanoparticle technology for the treatment of COVID-19, cancer and other diseases requiring targeted therapeutic delivery. In collaboration with highly acclaimed academic institutions such as UCSD and the University of Washington, along with recognized industry leaders, GCT aims to make novel therapies available to patients as quickly as possible. The company has already raised $1 million in a private placement. The SEC has recently qualified GCT to commence raising $9 Million under a Reg A+ registration. Sources: https://www.worldometers.info/coronavirus/?zarsrc=130 https://www.cnn.com/2020/12/27/health/us-coronavirus-sunday/index.html https://www.fda.gov/drugs/drug-safety-and-availability/fda-cautions-against-use-hydroxychloroquine-or-chloroquine-covid-19-outside-hospital-setting-or https://www.science.nus.edu.sg/blog/2018/08/29/perovskite-nanocrystal-scintillators-for-x-ray-imaging/

  • Facebook
  • LinkedIn
  • YouTube

THIS INVESTMENT INVOLVES A HIGH DEGREE OF RISK. THIS INVESTMENT IS SUITABLE ONLY FOR PERSONS WHO CAN BEAR THE ECONOMIC RISK FOR AN INDEFINITE PERIOD OF TIME AND WHO CAN AFFORD TO LOSE THEIR ENTIRE INVESTMENT. FURTHERMORE, INVESTORS MUST UNDERSTAND THAT SUCH INVESTMENT IS ILLIQUID AND IS EXPECTED TO CONTINUE TO BE ILLIQUID FOR AN INDEFINITE PERIOD OF TIME. NO PUBLIC MARKET EXISTS FOR THE SECURITIES, AND NO PUBLIC MARKET MAY DEVELOP FOLLOWING THIS OFFERING.

 

THE SECURITIES OFFERED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES OR BLUE SKY LAWS AND ARE BEING OFFERED AND SOLD IN RELIANCE ON EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT AND STATE SECURITIES OR BLUE SKY LAWS. ALTHOUGH AN OFFERING STATEMENT HAS BEEN FILED WITH THE SECURITIES AND EXCHANGE COMMISSION (THE “SEC”), THAT OFFERING STATEMENT DOES NOT INCLUDE THE SAME INFORMATION THAT WOULD BE INCLUDED IN A REGISTRATION STATEMENT UNDER THE SECURITIES ACT. THE SECURITIES HAVE NOT BEEN APPROVED OR DISAPPROVED BY THE SEC, ANY STATE SECURITIES COMMISSION OR OTHER REGULATORY AUTHORITY, NOR HAVE ANY OF THE FOREGOING AUTHORITIES PASSED UPON THE MERITS OF THIS OFFERING OR THE ADEQUACY OR ACCURACY OF THE SUBSCRIPTION AGREEMENT OR ANY OTHER MATERIALS OR INFORMATION MADE AVAILABLE TO SUBSCRIBERS IN CONNECTION WITH THIS OFFERING.

 

SUBSCRIBERS WHO ARE NOT “ACCREDITED INVESTORS” (AS THAT TERM IS DEFINED IN SECTION 501 OF REGULATION D PROMULGATED UNDER THE ACT) ARE SUBJECT TO LIMITATIONS ON THE AMOUNT THEY MAY INVEST, AS SET OUT IN SECTION 4. THE COMPANY IS RELYING ON THE REPRESENTATIONS AND WARRANTIES SET FORTH BY EACH SUBSCRIBER IN THIS SUBSCRIPTION AGREEMENT AND THE OTHER INFORMATION PROVIDED BY SUBSCRIBER IN CONNECTION WITH THIS OFFERING TO DETERMINE THE APPLICABILITY TO THIS OFFERING OF EXEMPTIONS FROM THE REGISTRATION REQUIREMENTS OF THE ACT.

 

THE OFFERING MATERIALS MAY CONTAIN FORWARD-LOOKING STATEMENTS AND INFORMATION RELATING TO, AMONG OTHER THINGS, THE COMPANY, ITS BUSINESS PLAN AND STRATEGY, AND ITS INDUSTRY. THESE FORWARD-LOOKING STATEMENTS ARE BASED ON THE BELIEFS OF, ASSUMPTIONS MADE BY, AND INFORMATION CURRENTLY AVAILABLE TO THE COMPANY’S MANAGEMENT. WHEN USED IN THE OFFERING MATERIALS, THE WORDS “ESTIMATE,” “PROJECT,” “BELIEVE,” “ANTICIPATE,” “INTEND,” “EXPECT” AND SIMILAR EXPRESSIONS ARE INTENDED TO IDENTIFY FORWARD-LOOKING STATEMENTS. THESE STATEMENTS REFLECT MANAGEMENT’S CURRENT VIEWS WITH RESPECT TO FUTURE EVENTS AND ARE SUBJECT TO RISKS AND UNCERTAINTIES THAT COULD CAUSE THE COMPANY’S ACTUAL RESULTS TO DIFFER MATERIALLY FROM THOSE CONTAINED IN THE FORWARD-LOOKING STATEMENTS. INVESTORS ARE CAUTIONED NOT TO PLACE UNDUE RELIANCE ON THESE FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE ON WHICH THEY ARE MADE. THE COMPANY DOES NOT UNDERTAKE ANY OBLIGATION TO REVISE OR UPDATE THESE FORWARD-LOOKING STATEMENTS TO REFLECT EVENTS OR CIRCUMSTANCES AFTER SUCH DATE OR TO REFLECT THE OCCURRENCE OF UNANTICIPATED EVENTS.

 

THE COMPANY MAY NOT BE OFFERING THE SECURITIES IN EVERY STATE. THE OFFERING MATERIALS DO NOT CONSTITUTE AN OFFER OR SOLICITATION IN ANY STATE OR JURISDICTION IN WHICH THE SECURITIES ARE NOT BEING OFFERED.

 

THE COMPANY RESERVES THE RIGHT IN ITS SOLE DISCRETION AND FOR ANY REASON WHATSOEVER TO MODIFY, AMEND AND/OR WITHDRAW ALL OR A PORTION OF THE OFFERING AND/OR ACCEPT OR REJECT IN WHOLE OR IN PART ANY PROSPECTIVE INVESTMENT IN THE SECURITIES OR TO ALLOT TO ANY PROSPECTIVE INVESTOR LESS THAN THE AMOUNT OF SECURITIES SUCH INVESTOR DESIRES TO PURCHASE. EXCEPT AS OTHERWISE INDICATED, THE OFFERING MATERIALS SPEAK AS OF THEIR DATE. NEITHER THE DELIVERY NOR THE PURCHASE OF THE SECURITIES SHALL, UNDER ANY CIRCUMSTANCES, CREATE ANY IMPLICATION THAT THERE HAS BEEN NO CHANGE IN THE AFFAIRS OF THE COMPANY SINCE THAT DATE.

© 2021 by Global Cancer Technology